Our investors

Founded in 2021, TCGX partners with intrepid innovators who can translate cutting-edge science into products that will make a meaningful difference for patients. TCGX manages ~$2 billion in capital and operates offices in San Francisco, Palo Alto, and New York City.

OrbiMed is a leading healthcare investment firm, with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 130 professionals is based in New York City, San Francisco, London, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Surveyor Capital Management is a global investment firm established in 2008 as part of Citadel. Specializing in long-term fundamental equity strategies, the firm employs deep research and sector-focused teams to identify investment opportunities. With approximately 190 professionals across major U.S. cities, Surveyor emphasizes rigorous risk controls and multi-factor hedging. The firm has made over 116 investments, showcasing its commitment to building strong relationships with company management teams. Known for its disciplined approach, Surveyor Capital Management aims to deliver superior returns while managing risk effectively.

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond.

Founded in 2004, Pontifax is a healthcare-dedicated venture capital firm with $1.2 billion under management. We seek transformative, cutting-edge life sciences technologies at all development stages. Our portfolio comprises of about 100 companies that develop breakthrough solutions to substantial unmet needs.

HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe. Since the start in 1996, HealthCap has backed and built more than 100 companies. HealthCap’s investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies which have the potential to be transformative and improve the lives of patients suffering from these conditions

Ysios Capital, a leading Spanish venture capital firm, provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages over 400M EUR through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies